ReviewFrontiers in immunology2014
Utility, limitations, and future of non-human primates for dengue research and vaccine development.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Dengue viruses cluster antigenically but not as discrete serotypes.Science (New York, N.Y.) · 2015Trial
- Development of attenuated and inactivated Dengue strains using advanced gene editing tools.Molecular biology reports · 2026Review
- Evaluation of Four Humanized NOD-Derived Mouse Models for Dengue Virus-2 Infection.Pathogens (Basel, Switzerland) · 2024Article
- A Novel, Comprehensive A129 Mouse Model for Investigating Dengue Vaccines and Evaluating Pathogenesis.Vaccines · 2023Article
- Infection order outweighs the role of CD4iScience · 2022Article
- Humanized Mice for the Study of Dengue Disease Pathogenesis: Biological Assays.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.Cell host & microbe · 2021Article
- Review
- Identifying potential human and medicinal plant microRNAs against SARS-CoV-2 3'UTR region: A computational genomics assessment.Computers in biology and medicine · 2021Article
- Animals as potential reservoirs for dengue transmission: A systematic review.One health (Amsterdam, Netherlands) · 2021Review
- Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).PLoS neglected tropical diseases · 2021Article
- Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications.Frontiers in immunology · 2021Review
- Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques.PLoS neglected tropical diseases · 2020Article
- Non-Human Primate Models of Dengue Virus Infection: A Comparison of Viremia Levels and Antibody Responses during Primary and Secondary Infection among Old World and New World Monkeys.Pathogens (Basel, Switzerland) · 2020Review
- A Review on Dengue Vaccine Development.Vaccines · 2020Review
- Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design.Frontiers in immunology · 2020Review
- Using Macaques to Address Critical Questions in Zika Virus Research.Annual review of virology · 2019Review
- Time elapsed between Zika and dengue virus infections affects antibody and T cell responses.Nature communications · 2019Article
- Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes.PLoS pathogens · 2019Article
- Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.PLoS pathogens · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Dengue is considered the most important emerging, human arboviruses, with worldwide distribution in the tropics. Unfortunately, there are no licensed dengue vaccines available or specific anti-viral drugs. The development of a dengue vaccine faces unique challenges. The four serotypes co-circulate in endemic areas, and pre-existing immunity to one serotype does not protect against infection with other serotypes, and actually may enhance severity of disease. One foremost constraint to test the efficacy of a dengue vaccine is the lack of an animal model that adequately recapitulates the clinical manifestations of a dengue infection in humans. In spite of this limitation, non-human primates (NHP) are considered the best available animal model to evaluate dengue vaccine candidates due to their genetic relatedness to humans and their ability to develop a viremia upon infection and a robust immune response similar to that in humans. Therefore, most dengue vaccines candidates are tested in primates before going into clinical trials. In this article, we present a comprehensive review of published studies on dengue vaccine evaluations using the NHP model, and discuss critical parameters affecting the usefulness of the model. In the light of recent clinical data, we assess the ability of the NHP model to predict immunological parameters of vaccine performances in humans and discuss parameters that should be further examined as potential correlates of protection. Finally, we propose some guidelines toward a more standardized use of the model to maximize its usefulness and to better compare the performance of vaccine candidates from different research groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.